RTSN

Pre-Market Hot Trades in US Stocks

Retension Pharmaceuticals, up 13.59% in pre-market trading, with no significant news recently. Trading is active with clear capital flows. Considering sector and industry trends, the stock shows notable volatility, and the specific reasons require further observation.

Saverone 2014, down 9.50% in pre-market trading, with no significant news recently. Trading is active with clear capital flows. Considering sector and industry trends, the stock shows notable volatility, and the specific reasons require further observation.

Top Gainers in US Pre-Market Trading

CL Workshop, up 130.92% in pre-market trading, with no significant news recently. Trading is active with clear capital flows. Considering sector and industry trends, the stock shows notable volatility, and the specific reasons require further observation.

WISeSat Space up 55.72% in pre-market trading. Based on recent key news:

1. On October 20, WISeSat Space Holdings participated in a commercial space infrastructure project, driving a significant surge in its stock price. The company demonstrates growth potential among mid-cap stocks. Although Wall Street attention has been relatively low, its contributions to the commercial space sector have sparked market interest, leading to a 55.72% pre-market jump. The technology sector performed strongly with evident capital inflows.

Rapport Therapeutics up 52.06% in pre-market trading. Based on recent key news:

1. On October 20, Rapport Therapeutics announced positive results from Phase II trials of RAP-219 for the treatment of bipolar disorder. RAP-219 achieved a placebo-adjusted improvement of 3.1 points at Week 3, with patients' average Young Mania Rating Scale (YMRS) score decreasing by 15.4 points. The drug was well-tolerated, with only mild or moderate adverse events reported. This news drove a significant rise in the stock price. Source: Reuters

2. On October 18, Wells Fargo analyst Benjamin Burnett maintained a Buy rating on Rapport Therapeutics and set a target price of $51. The market consensus is strongly bullish on the company, with an average target price of $59.38, implying an upside potential of 115.38% from current levels. Analysts' optimistic expectations further boosted market confidence. Source: TipRanks

3. On October 20, Rapport Therapeutics planned to meet with the FDA in the first quarter of 2027 to discuss the Phase III trial design for RAP-219, and expects to initiate two Phase III trials in the second half of 2027. This plan highlights the company's active progress in R&D, strengthening investor confidence. Source: Reuters Progress in pharmaceutical industry R&D drives stock price volatility.